Friday 31 Jan, 2025 08:19 PM
Site map | Locate Us | Login
   IndusInd Bank Q3 PAT tumbles 39% YoY to Rs 1,401 crore in FY25    Sun Pharma PAT rises 15% YoY to Rs 2,903 crore in Q3    Vedanta gains after Q3 PAT rises 70% YoY to Rs 4,876 cr    UPL spurts on reporting turnaround Q3 numbers in FY25    Panama Petrochem records PAT of Rs 30.48 crore in Q3    Vakrangee Ltd leads losers in 'A' group    Marico Q3 PAT rises 4% YoY to Rs 399 crore in FY25;declares dividend of Rs 3.50/sh    Punjab National Bank rallies as Q3 PAT doubles to Rs 4,508 crore    DE Nora India Ltd leads losers in 'B' group    Volumes jump at Whirlpool of India Ltd counter    Navin Fluorine Intl jumps after Q3 PAT rises 7% YoY to Rs 84 cr    Power Finance Corporation Ltd soars 1.4%, up for third straight session    REC Ltd soars 2.42%, Gains for third straight session    Gujarat Gas Ltd gains for third straight session    Coal India Ltd spurts 1.47%, rises for third straight session 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Sun Pharma PAT rises 15% YoY to Rs 2,903 crore in Q3
31-Jan-25   16:13 Hrs IST

Profit before exceptional items and tax was at Rs 3,792.57 crore in the December 2024 quarter, registering a growth of 23.53% on a YoY basis.

During the quarter, EBITDA stood at Rs 4,009 crore (including other operating revenues), up 15.3% with resulting EBITDA margin of 29.3%

Sales of Formulation in India for Q3 FY25 were at Rs 4,300.4 crore, up 13.8% YoY and accounting for approximately 32% of total consolidated sales.

US Formulation sales were $474 million in Q3 FY25, down 0.7% YoY and accounting for approximately 30% of total consolidated sales.

Formulation sales in emerging markets were $277 million for the third quarter of FY25, growing by 10.1% YoY and accounted for approximately 17% of total consolidated sales.

Formulation sales in rest of world (ROW) markets excluding India, the US, and emerging markets were $259 million in Q3 of FY25, up 21% YoY and accounted for 16% of total consolidated sales.

During the quarter, external sales of API stood at Rs 567.8 crore, up 21.8% YoY. The company said that its API portfolio supports the formulation business and API customers across geographies.

Consolidated R&D investment was at Rs 845 crore for Q3 FY25 or 6.3% of sales as compared to Rs 824.5 crore for Q3 FY24.

On a nine-month basis, the company's consolidated net profit increased 26.83% to Rs 8,779.16 crore on an 8.51% rise in revenue from operations to Rs 39,619.60 crore in 9M FY25 over 9M FY24.

The drug maker stated that it has a comprehensive product offering in the US market consisting of approved ANDAs for 541 products while filings for 109 ANDAs await US FDA approval, including 28 tentative approvals. Additionally, the portfolio includes 51 approved NDAs while 13 NDAs await US FDA approval. For the quarter, 6 ANDA were filed and 2 ANDA approvals were received.

Dilip Shanghvi, chairman and MD, said, 'Our performance in the quarter showed all-round improvement. Product sales in Global Specialty crossed 1/5th of overall sales. Our market share gain in India has been driven by industry leading volume growth. Emerging Markets demonstrated strong performance in spite of currency challenges across geographies. All our businesses remain well positioned for future.

Meanwhile, the board declared an interim dividend of Rs 10.50 per equity share for FY25, and the record date for the same is 6 February 2025. The interim dividend shall be paid on or before 20 February 2025.

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company.

The scrip declined 0.12% to close at Rs 1,743.10 on the BSE.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 38600929
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd